Xác định chữ ký dự đoán điều trị cá nhân hóa cho ung thư biểu mô tế bào vảy vùng đầu và cổ

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–83. Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–96. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. Beesley LJ, Hawkins PG, Amlani LM, Bellile EL, Casper KA, Chinn SB, Eisbruch A, Mierzwa ML, Spector ME, Wolf GT, et al. Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era. Cancer. 2019;125(1):68–78. Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008;35(3):221–8. Li G, Jiang Y, Li G, Qiao Q. Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma. Radiother Oncol. 2021;159:126–35. Kim SI, Kang JW, Noh JK, Jung HR, Lee YC, Lee JW, Kong M, Eun YG. Gene signature for prediction of radiosensitivity in human papillomavirus-negative head and neck squamous cell carcinoma. Radiat Oncol J. 2020;38(2):99–108. Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017;6(10): e1356153. Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, et al. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer. 2015;137(12):2846–57. Ding L, Sishc BJ, Polsdofer E, Yordy JS, Facoetti A, Ciocca M, Saha D, Pompos A, Davis AJ, Story MD. Evaluation of the Response of HNSCC Cell Lines to gamma-Rays and (12)C Ions: Can Radioresistant Tumors Be Identified and Selected for (12)C Ion Radiotherapy? Front Oncol. 2022;12: 812961. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. Ren J, Du Y, Li S, Ma S, Jiang Y, Wu C. Robust network-based regularization and variable selection for high-dimensional genomic data in cancer prognosis. Genet Epidemiol. 2019;43(3):276–91. Wu C, Ma S. A selective review of robust variable selection with applications in bioinformatics. Brief Bioinform. 2015;16(5):873–83. Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289–99. Gregoire V, Langendijk JA, Nuyts S. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol. 2015;33(29):3277–84. Lacas B, Bourhis J, Overgaard J, Zhang Q, Gregoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwinski R, Poulsen M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–37. Yamamoto VN, Thylur DS, Bauschard M, Schmale I, Sinha UK. Overcoming radioresistance in head and neck squamous cell carcinoma. Oral Oncol. 2016;63:44–51. Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck. 2015;37(5):763–70. Fleschutz K, Walter L, Leistner R, Heinzerling L. ALK inhibitors do not increase sensitivity to radiation in EML4-ALK non-small cell lung cancer. Anticancer Res. 2020;40(9):4937–46. Li P, Liu X, Zhao T, Li F, Wang Q, Zhang P, Hirayama R, Chen W, Jin X, Zheng X, et al. Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities. Cell Death Discov. 2021;7(1):184. Lalani N, Voduc KD, Jimenez RB, Levasseur N, Gondara L, Speers C, Lohrisch C, Nichol A. Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity. Int J Radiat Oncol Biol Phys. 2021;109(1):281–7. Cui J, Wang M-C, Zhang Y-M, Ren M-Z, Wang S-X, Nan K-J, Song L-P. Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells. Cancer Chemother Pharmacol. 2018;81(4):717–26. Shi M, Wan J, Wang H, Yu H. Cytokeratin 13 promotes radiotherapy sensitivity of nasopharyngeal carcinoma by downregulating the MEK/ERK pathway. IUBMB Life. 2022;74(6):543–53. Zhang H, Fang C, Feng Z, Xia T, Lu L, Luo M, Chen Y, Liu Y, Li Y. The role of LncRNAs in the regulation of radiotherapy sensitivity in cervical cancer. Front Oncol. 2022;12: 896840. Tran VT, Phan TT, Nguyen ST, Tran B-T, Ho TT, Pho SP, Nguyen TB, Pham TTB, Le AT, Le VT, et al. Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer. BMC Res Notes. 2020;13(1):367. Yun Y, Zhang Y, Xu Q, Ou Y, Zhou X, Lu Z. SOX17-mediated MALAT1-miR-199a-HIF1α axis confers sensitivity in esophageal squamous cell carcinoma cells to radiotherapy. Cell Death Discov. 2022;8(1):270. Anbalagan S, Ström C, Downs JA, Jeggo PA, McBay D, Wilkins A, Rothkamm K, Harrington KJ, Yarnold JR, Somaiah N. TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells. Sci Rep. 2021;11(1):7119. Ma Q, Geng K, Xiao P, Zeng L. Identification and prognostic value exploration of radiotherapy sensitivity-associated genes in non-small-cell lung cancer. Biomed Res Int. 2021;2021:5963868. Feng Y, Li G, Shi Z, Yan X, Wang Z, Jiang H, Chen Y, Li R, Zhai Y, Chang Y, et al. A novel methylation signature predicts radiotherapy sensitivity in glioma. Sci Rep. 2020;10(1):20406. Chen X, Zheng J, Zhuo ML, Zhang A, You Z. A six-gene-based signature for breast cancer radiotherapy sensitivity estimation. Biosci Rep. 2020;40(12):BSR20202376. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang Z-Q, et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114(12):1352–61. Wang L, Wang L, Zhang H, Lu J, Zhang Z, Wu H, Liang Z. AREG mediates the epithelial-mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF-κB signalling pathway. Oncol Rep. 2020;43(5):1558–68. Tung SL, Huang WC, Hsu FC, Yang ZP, Jang TH, Chang JW, Chuang CM, Lai CR, Wang LH. miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis. 2017;6(5): e326. Stiehl DP, Bordoli MR, Abreu-Rodríguez I, Wollenick K, Schraml P, Gradin K, Poellinger L, Kristiansen G, Wenger RH. Non-canonical HIF-2α function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene. 2012;31(18):2283–97. Gu X, Li H, Sha L, Mao Y, Shi C, Zhao W. CELSR3 mRNA expression is increased in hepatocellular carcinoma and indicates poor prognosis. PeerJ. 2019;7: e7816. Zheng K, Lan T, Li G-P, Huang L, Chen Y-P, Su B-H, Zhang S, Zheng D-L. Evaluated expression of CELSR3 in oral squamous cell carcinoma is associated with perineural invasion and poor prognosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133(5):564–73. Chen X, Ma Q, Liu Y, Li H, Liu Z, Zhang Z, Niu Y, Shang Z. Increased expression of CELSR3 indicates a poor prognostic factor for prostate cancer. J Cancer. 2021;12(4):1115–24. Li Y, Zhu L, Hao R, Li Y, Zhao Q, Li S. Systematic expression analysis of the CELSR family reveals the importance of CELSR3 in human lung adenocarcinoma. J Cell Mol Med. 2021;25(9):4349–62. Zhang L, Wang X. An Immune-Related Gene Signature Can Predict Clinical Outcomes and Immunotherapeutic Response in Oral Squamous Cell Carcinoma. Front Genet. 2022;13: 870133. Belotti Y, Lim SB, Iyer NG, Lim W-T, Lim CT. Prognostic Matrisomal Gene Panel and Its Association with Immune Cell Infiltration in Head and Neck Carcinomas. Cancers (Basel). 2021;13(22):5761. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer. 2009;9:237. Maestri CA, Nisihara R, Mendes HW, Jensenius J, Thiel S, Messias-Reason I, de Carvalho NS. MASP-1 and MASP-2 serum levels are associated with worse prognostic in cervical cancer progression. Front Immunol. 2018;9:2742. Ghiani L, Chiocca S. High Risk-Human Papillomavirus in HNSCC: Present and future challenges for epigenetic therapies. Int J Mol Sci. 2022;23(7):3483. Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, et al. Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: The ORATOR2 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(6):1–7. Berdugo J, Rooper LM, Chiosea SI. RB1, p16, and human papillomavirus in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2021;15(4):1109–18. Cho J-K, Kim MW, Choi IS, Moon UY, Kim M-J, Sohn I, Kim S, Jeong H-S. Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study. BMC Cancer. 2018;18(1):969. Sinha N, Sinha S, Valero C, Schäffer AA, Aldape K, Litchfield K, Chan TA, Morris LGT, Ruppin E. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer Res. 2022;82(11):2076–83. Lv J, Liu YY, Jia YT, He JL, Dai GY, Guo P, Zhao ZL, Zhang YN, Li ZX. A nomogram model for predicting prognosis of obstructive colorectal cancer. World J Surg Oncol. 2021;19(1):337. Lin Y-W, Kang W-P, Huang B-L, Qiu Z-H, Wei L-F, Zhang B, Ding T-Y, Luo Y, Liu C-T, Chu L-Y, et al. Nomogram based on clinical characteristics and serological inflammation markers to predict overall survival of oral tongue squamous cell carcinoma patient after surgery. BMC Oral Health. 2021;21(1):667.